Genmab A (GMAB) Cash from Operations (2018 - 2026)

Genmab A has reported Cash from Operations for 7 years, with the latest figure at 3000000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 98.95% year-over-year to 3000000.0; the trailing twelve-month figure through Mar 2026 stood at 1175000000.0 (down 5.47% YoY), and the FY2025 full-year result was 1186000000.0, up 5.33% from the prior year.
• Cash from Operations for Q1 2026 stood at 3000000.0, down from 536000000.0 in the prior quarter.
• The five-year high for Cash from Operations was 536000000.0 in Q3 2025, with the low at 4637000000.0 in Q4 2023.
• Historically, Cash from Operations has averaged 313250000.0 across 4 years, with a median of 293000000.0 in 2024.
• Annual changes were most pronounced in 2025 — Cash from Operations surged 79.26% — and 2026, when it slumped 98.95%.
• Genmab A's Cash from Operations stood at 4637000000.0 in 2023, then soared by 106.45% to 299000000.0 in 2024, then surged by 79.26% to 536000000.0 in 2025, then plunged by 99.44% to 3000000.0 in 2026.
• The last three Cash from Operations figures came in at 3000000.0 (Q1 2026), 536000000.0 (Q3 2025), and 349000000.0 (Q2 2025), per Business Quant data.